

## CD40-CD40 Ligand Interactions in the Production of IL-12 and IFN- $\gamma$ by Tuberculous Pleural Mononuclear Cells

Chang-Hwa Song<sup>1</sup>, Hyun-Hee Nam<sup>1</sup>, Jeun-Ok An<sup>1</sup>, Ji-Sook Lee<sup>1</sup>, Hwa-Jung Kim<sup>1</sup>, Jeong-Kyu Park<sup>1</sup>, Ji-Won Suhr<sup>2</sup>, Sung-Soo Jung<sup>3</sup>, Moon-Jun Na<sup>4</sup>, Tae-Hyun Paik<sup>5</sup> and Eun-Kyeong Jo<sup>1</sup>

Departments of <sup>1</sup>Microbiology and <sup>3</sup>Internal Medicine, College of Medicine, Chungnam National University, Daejeon; <sup>2</sup>Department of Internal Medicine, Catholic University, Daejeon; Departments of <sup>4</sup>Internal Medicine and <sup>5</sup>Microbiology, College of Medicine, Konyang University, Chungnam, Korea

### ABSTRACT

**Background:** Our previous study showed that purified protein derivative (PPD)-stimulated pleural mononuclear cells (PMC) from tuberculous pleurisy (Tbp) produced significantly more IFN- $\gamma$  (10- to 70-fold) after *in vitro* PPD stimulation than freshly isolated pleural cells from malignant pleurisy. The present study was designed to determine whether blocking the CD40-CD40 ligand (CD40L) interaction decreases IFN- $\gamma$  production by altering IL-12 levels. **Methods:** IL-12 and IFN- $\gamma$  production after neutralizing anti-CD40L antibody treatment was compared to the efficacy of anti-CD80, anti-CD86, and a combination of anti-CD80 and CD86 (CD80+86) monoclonal antibodies (mAb). These activities were measured by enzyme-linked immunosorbent assays (ELISAs) and reverse transcription-polymerase chain reaction (RT-PCR), after *in vitro* stimulation with PPD antigen (Ag). **Results:** Neutralization of CD80, CD86 and CD80+86 did not decrease IFN- $\gamma$  and IL-12 production in Tbp-PMC, whereas neutralization of CD40L significantly depressed IL-12 p40 and IFN- $\gamma$ . In addition, neutralization of CD40L completely inhibited IL-12 p40 and IFN- $\gamma$  mRNA expression. **Conclusion:** The CD40-CD40L interaction might play a major role in IL-12 and IFN- $\gamma$  production in Tbp-PMC, thus contributing to protective immunity in human tuberculosis. (*Immune Network* 2002;2(3):142-149)

**Key Words:** CD40 ligand, tuberculous pleurisy, pleural mononuclear cells, CD80, CD86, PPD antigen, 30-kDa antigen

### Introduction

Tuberculous pleurisy (Tbp) is a good model for understanding local cellular immunity. Tuberculous pleural effusions typically show a predominance of T lymphocytes (1,2), especially CD4+ T cells (2,3), and release high levels of interferon (IFN)- $\gamma$  (4-7). IFN- $\gamma$ , a product of activated T and NK cells, has a major role in activating cell-mediated immunity and contributes to a host's defense against intracellular bacterial infections (8,9). Purified protein derivatives (PPD), a mixture of low-molecular weight proteins from *Mycobacterium tuberculosis*, stimulate the produc-

tion of cytokines implicated in Th1 differentiation, such as IFN- $\gamma$  (10,11). In Tbp, PPD-stimulated pleural fluid cells produce higher amounts of IFN- $\gamma$  than peripheral blood mononuclear cells (12). This local immune response, orchestrated by T cells and by a cytokine network, seems to be involved in the favorable outcome of Tbp patients, and may represent the protective immune response invoked to control the spread of *M. tuberculosis* infection (13).

Our previous study showed that interleukin (IL)-12 levels were significantly increased in pleural effusions from Tbp patients (14), and there is evidence that IL-12 is a potent stimulator of IFN- $\gamma$  production (15). IL-12 is an inducible, heterodimeric, disulfide-linked cytokine composed of 35- and 40-kDa subunits encoded by separate genes (16). This cytokine induces IFN- $\gamma$  production, primarily by NK cells, thereby activating the phagocytic cell system as a first line of natural defense. In addition, the early induction of IL-12 is necessary for the optimal generation

Correspondence to: Eun-Kyeong Jo, Department of Microbiology, College of Medicine, Chungnam National University, 6 Munhwa-dong, Jung-gu, Daejeon 301-747, Korea. (Tel) 82-42-580-8243, (Fax) 82-42-585-3686, (E-mail) hayoungj@cnu.ac.kr  
This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (01-PJ10-PG6-01GM03-002).

of T helper type 1 (Th1) CD4<sup>+</sup> cells (15). IL-12 mRNA production is elevated at the site of tuberculosis infection and neutralizing IL-12 suppressed the proliferative responses of pleural fluid cells to *M. tuberculosis*, suggesting that IL-12 plays a role in the human immune response to infectious agents *in vivo* (11).

CD40/CD40 ligand (CD40L) co-stimulation is an important regulator of Th1 responses (17). This co-stimulation has a potent effect on the production of IL-12 and IFN- $\gamma$  in cells stimulated with T-cell-specific Ags (17). In addition, CD40L and IFN- $\gamma$  synergistically restore IL-12 production in HIV-infected patients (18). However, the role of CD40/CD40L stimulation in tuberculosis is controversial. A recent study reported that the CD40L-mediated pathway of T-cell activation is dispensable for resistance to *M. tuberculosis* infection (19). This was in contrast to the enhanced susceptibility of patients with a defective CD40L gene (20) to other experimental infections with intracellular pathogens, including *Leishmania* (21).

The current study was undertaken to further characterize the Th1 regulatory mechanisms attributable to Th1 elevation in Tbp after *in vitro* stimulation with PPD Ag via CD40/CD40L interaction. The production of IFN- $\gamma$  and IL-12 in PPD Ag-stimulated PMC from 12 patients with tuberculous pleurisy (Tbp-PMC) was compared with that of PMC from 10 patients with malignant effusions (MG-PMC). In response to Ag, both IL-12 and IFN- $\gamma$  were found to increase significantly in Tbp-PMC. In addition, blocking CD40/CD40L interactions also decreased IL-12 and IFN- $\gamma$  production in Tbp-PMC. Neither separate nor simultaneous neutralization of CD80 and CD86 led to a change in IL-12 and IFN- $\gamma$  production.

## Materials and Methods

**Subjects.** Twelve HIV-negative patients with Tbp, and without a history of previous anti-tuberculous therapy or diabetes mellitus were included in this study. Tbp was diagnosed by the histopathological finding of granulomas with caseous necrosis in pleural biopsies, or by a positive culture of *M. tuberculosis* from biopsy specimens. Pleural exudate cells were obtained from drained pleural fluid obtained routinely for diagnosis and as part of the treatment of the Tbp patients. Pleural effusions were also collected from 10 patients with newly diagnosed lung cancer with malignant effusion (MG).

Five healthy tuberculin reactors (HTR) exhibited skin reactions of more than 15 mm after an intradermal test with 5 units of PPD-RT23 (Statens Seruminstitut, Copenhagen, Denmark), drawn within 1 to

3 years of their PPD skin test examination, and had no previous history of clinical TB. Each of these healthy controls had received *Mycobacterium bovis* Bacille Calmette-Guerin (BCG) vaccinations as children. All patients and healthy volunteers consented to take part in this study.

**Antigen and antibodies.** Tuberculin PPD for *in vitro* assays was purchased from the Statens Seruminstitut (Copenhagen, Denmark), and was used at a final concentration of 1.0 mg/ml. Endotoxin content was measured by the *Limulus* amoebocyte lysate assay and was found to be below 1.5 pg/ml in PPD Ag. Neutralizing anti-human CD40L antibodies (5c8) were kindly provided by Dr. Shigeaki Nonoyama (Tokyo Medical and Dental University, Tokyo, Japan). Neutralizing anti-human CD80 and CD86 were purchased from R&D Systems (Minneapolis, MN, USA). For flow cytometric analysis, fluorescein isothiocyanate (FITC)-labelled anti-CD3, and phycoerythrin (PE)-labelled anti-CD40L were purchased from Pharmingen (San Diego, CA, USA).

**Two-color immunocytometry.** Fresh or mycobacterial antigen stimulated mononuclear cells were resuspended at  $2 \times 10^6$  to  $5 \times 10^6$  cells/ml in staining buffer (phosphate-buffered saline-2% human serum-1% bovine serum albumin-0.02% sodium azide) containing a saturated amount of antibodies, and incubated for 30 min at 4°C. After staining, the cells were washed three times with staining buffer and analyzed with a FACScalibur (Becton & Dickinson Immunocytometry, San Jose, CA, USA). Data were represented as two-dimensional contour maps. To obtain the percentage of a subpopulation, total counts were integrated in selected areas of contour plots. Background staining of the negative control Ig was subtracted from experimental values.

**Preparation and stimulation of peripheral blood mononuclear cells.** Venous blood was drawn from subjects into sterile blood-collection tubes and peripheral blood mononuclear cells (PBMC) were isolated by density sedimentation over Histopaque-1077 (Sigma, St. Louis, MO, USA). PBMC were then suspended at a density of  $1 \times 10^6$  viable cells/ml in complete medium [RPMI 1640, (Gibco-BRL, Gaithersburg, MD, USA) with 10% fetal bovine serum (Gibco-BRL), sodium pyruvate, non-essential amino acids, penicillin G (100 IU/ml), and streptomycin (100  $\mu$ g/ml)]. Cells were then stimulated with PPD antigen (1.0  $\mu$ g/ml), phytohemagglutinin (PHA, 10  $\mu$ g/ml; Sigma), or lipopolysaccharide (LPS, 0.1  $\mu$ g/ml; Sigma) and incubated at 37°C in a 5% CO<sub>2</sub> humidified air atmosphere until being used for either RNA isolation or supernatant collection.

As a positive control in the evaluation of CD40L expression, PBMC were prepared by Ficoll-Hypaque

gradient centrifugation, and cultured with phorbol 12-myristate 13-acetate (10 ng/mL) (Sigma) and ionomycin (400 ng/mL) (Calbiochem-Novabiochem Corp, La Jolla, CA) for 8 h.

*Enzyme-linked immunosorbent assay for IFN- $\gamma$ , IL-12 p40, and IL-12 p70.* Supernatants were collected from cultures of PBMC stimulated with PPD Ag at 18 (for IL-12 p40 and p70), and 96 (for IFN- $\gamma$ ) h, and were then frozen at 80°C. The frozen supernatants were thawed at room temperature, and cytokine levels were measured with commercial assay kits for IFN- $\gamma$ , IL-12 p70, and IL-12 p40 (PharMingen), according to the manufacturers' instructions. Cytokine concentrations in the samples were calculated with standard curves generated from recombinant cytokines, and the results were expressed in picograms per milliliter. The difference between duplicate wells was consistently less than 100% of the mean.

*Reverse transcriptase polymerase chain reaction (RT-PCR).* PMC and PBMC were collected and washed, and total RNA was isolated using an RNeasy kit (Qiagen, Madison, WI) from cultures at various time points. First-strand cDNA synthesis and PCR were performed as previously described (22). All the PCR reactions were performed using 1  $\mu$ l cDNA and 2 U AmpliTaq DNA polymerase (Perkin-Elmer) in 20- $\mu$ l reaction mixtures in a thermocycler (Biometra Inc., Tampa, FL). Each cycle consisted of 1 min at 95°C, 1 min at 60°C, 1 min at 72°C, and a final extension step of 5 min at 72°C. An external control, the housekeeping gene  $\beta$ -actin, was used to normalize the starting amount of cDNA for each sample prior to PCR.

*Statistical methods.* The results are presented as the mean  $\pm$  SD. Statistical significance was calculated using Student's *t*-test, ANOVA or linear regression analysis.

## Results


*IFN- $\gamma$  production in patients with tuberculous pleurisy, malignancy, and healthy tuberculin reactors.* PMC was isolated from patients, cultured in the presence of PPD Ag for 96 h, and assayed by ELISA for IFN- $\gamma$  production. To measure IFN- $\gamma$  production in a logarithmic range, we performed IFN- $\gamma$  ELISA with serially (20- to 100-fold) diluted supernatants. As shown in Fig. 1, the mean pleural fluid IFN- $\gamma$  level was significantly higher in Tbp patients than in both patients with malignancy (2837.7  $\pm$  4620.6 versus 41.7  $\pm$  33.9 pg/ml,  $p < 0.001$ ), and HTR serum (8.1  $\pm$  7.8 pg/ml,  $p < 0.001$ ). In addition, the mean IFN- $\gamma$  concentration in the supernatants from PPD-stimulated Tbp-PMC was significantly higher than the corresponding values for MG-PMC (48.0  $\pm$  18.8 versus 0.2  $\pm$  0.2 ng/ml;  $p < 0.001$ ), and HTR-PBMC (898.3  $\pm$

402.5 pg/ml,  $p < 0.001$ ). IFN- $\gamma$  levels were more than 16-fold higher in supernatants from Ag-stimulated Tbp-PMC than in those from freshly isolated Tbp-PMC, whereas MG-PMC exhibited smaller (3.7-fold) increases in IFN- $\gamma$  production.


*IL-12 p40 production in patients with tuberculous pleurisy, malignancy, and healthy tuberculin reactors.* The levels of IL-12 p70 and p40 after co-culture with PPD for 18 h were determined using ELISA. In preliminary experiments, IL-12 p70 release correlated strongly with IL-12 p40 release ( $n=11$ ,  $r=0.81$ ,  $p < 0.001$ ; data not shown). Unstimulated Tbp-PMC showed detectable levels of IL-12 p70 (62.1  $\pm$  35.0 pg/ml), and these were significantly higher in Tbp patients than in patients with malignancy ( $p < 0.05$ ; data not shown).

As shown in Fig. 2(A), the mean IL-12 p40 production increased significantly in Tbp-PMC after stimulation with PPD when compared with cells before stimulation (1584.2  $\pm$  791.3 pg/ml versus 708.3  $\pm$  289.2 pg/ml,  $p < 0.01$ ), or when compared with the IL-12 p40 level in MG-PMC after stimulation with PPD (248.1  $\pm$  446.3 pg/ml,  $p < 0.001$ ). In addition, the mean IL-12 p40 concentrations in PPD-stimulated Tbp-PMC cultures were significantly higher than those in HTR-PBMC cultures (1584.2  $\pm$  791.3 versus 487.0  $\pm$  308.0 pg/ml,  $p < 0.001$ ). There was no significant difference in IL-12 p40 production between PPD-stimulated MG-PMC and HTR-PBMC (248.1  $\pm$  446.3 pg/ml versus 487.0  $\pm$  308.0 pg/ml,  $p > 0.05$ ).

We also observed that the production of IL-12 p40 in Tbp-PMC from individual patients correlated



**Figure 1.** IFN- $\gamma$  production of pleural mononuclear cells from the patients with tuberculous pleurisy after *in vitro* stimulation with the PPD antigen of *Mycobacterium tuberculosis*. Supernatants were prepared after the incubation periods indicated (96 h), and IFN- $\gamma$  production was measured by ELISA. Values are means  $\pm$  SD of triplicate supernatant samples.



**Figure 3.** Phenotypic analysis by FACS of CD40L expression from Tuberc and PBMC were cultured with 1µg/ml of PPD antigen from *M. tuberculosis*. CD40L molecules in T cells by flow cytometry. Freshly isolated PMC or data correspond representative experiments. (A) PPD-stimulated PMC in healthy tuberculin reactors. (C) PBMC after PMA plus ionomycin for 12 h. IL-12 p40 production of pleural mononuclear cells from the PPD antigen of *Mycobacterium tuberculosis*. Supernatants were prepared for IL-12 p40 and IFN-γ production in tuberculous pleurisy patients. IL-12 p40 and IFN-γ release was measured by ELISA. Values are means±SD of triplicate samples. *A*, IFN-γ production; and *B*, I



**Figure 4.** RT-PCR analysis of cDNA after *in vitro* stimulation with the PI and PBMC were cultured with 1µg/ml of PPD antigen from *M. tuberculosis*. HTR-PBMC were cultured for various times, as indicated, in the presence of the antigen. A PCR with primers specific for each cytokine gene was performed. The PCR products were analyzed by agarose gel electrophoresis. *A* shows IFN-γ mRNA expression in HTR-PBMC. *M*, molecular weight marker; 1, control; 2, mRNA from PPD-stimulated PMC/PBMC; 3, mRNA from PPD-stimulated Tbp-PMC; 4, mRNA from PPD-stimulated Tbp-PMC with anti-CD80; 5, mRNA from PPD-stimulated Tbp-PMC with anti-CD86; 6, mRNA from PPD-stimulated Tbp-PMC with anti-CD80/86. *B* shows IL-12 p40 mRNA expression in HTR-PBMC. *M*, molecular weight marker; 1, control; 2, mRNA from PPD-stimulated PMC/PBMC; 3, mRNA from PPD-stimulated Tbp-PMC; 4, mRNA from PPD-stimulated Tbp-PMC with anti-CD80; 5, mRNA from PPD-stimulated Tbp-PMC with anti-CD86; 6, mRNA from PPD-stimulated Tbp-PMC with anti-CD80/86. *A*, IFN-γ production; and *B*, I

lation with PPD (n=11, r=0.7, p=0.01; Fig. 2B). *CD40 ligand expression in patients with tuberculous pleurisy and healthy tuberculin reactors.* As a preliminary investigation into the CD40/CD40L interaction in PMC and PBMC, CD3 and CD40L expressing T cells were assessed by flow cytometry. The mean percentage of CD3+ T cells of HTR controls (n=5) increased from 45.2±6.5% to 60.9±24.2% in response to the PPD antigen. Similarly, CD3+ T cells in Tbp-PMC (n=7) increased from 78.0±2.5% to 90.5±12.5% in response to PPD.

One of the representative experiments for CD40L expression in response to mycobacterial antigen is shown in Fig. 3. The mean levels of CD40L/CD3 expression were after stimulation with PPD, increasing from 7.6±2.0% to 26.0±9.2%, and from 16.0±5.7% to 34.3±7.4%, in HTR and Tbp-PMC, respectively. This indicates that CD40L expressing T cells of HTR-PBMC and Tbp-PMC preferentially respond to the PPD antigen of *M. tuberculosis*.

*Effect of the neutralization of CD80, CD86, and CD40 ligands on PPD-induced IL-12 p40 and IFN-γ production in patients with tuberculous pleurisy and healthy tuberculin reactors.*

**RT-PCR:** We assessed the effect of CD80, CD86, and CD40L neutralization on PPD-induced IL-12 p40 and IFN-γ mRNA expression. HTR-PBMC and Tbp-PMC were cultured in complete RPMI with or without PPD (1µg/ml) in the presence or absence of neutralizing antibodies to CD80, CD86, and CD40L (1µg/ml).

Total RNA was extracted at 6 and 96 h, and levels

of cytokine mRNA were determined by RT-PCR. A representative experiment illustrating the pattern of IL-12 p40 and IFN-γ mRNA induced by the PPD in Tbp-PMC and HTR-PBMC is shown in Fig. 4. Cytokine mRNA production was evaluated by visual comparison of the intensity of the band representing PCR product from antigen-stimulated cells with those from freshly isolated (negative control) or PHA-stimulated cells (positive control). After PPD treatment, IFN-γ mRNA from PBMC was detected at 6 h, with increased detection at 48 h. IFN-γ mRNA levels then fell slightly at 96 h. IFN-γ mRNA expression was also clearly observed in PPD-stimulated Tbp-PMC in the presence of anti-CD80 or CD86 at 48 h. However, IFN-γ mRNA expression was low in PPD-stimulated Tbp-PMC with both anti-CD80 and CD86. Interestingly, IFN-γ mRNA expression was very low after neutralization of CD40L molecules at 48 h, and expression could not be observed at 96 h (Fig. 4A). In addition, IFN-γ mRNA levels were significantly reduced in PPD-stimulated PMC with anti-CD80, anti-CD86 or both at 96 h.

As shown in Fig. 4(B), IL-12 p40 mRNA expression after a 6-h stimulation in Tbp-PMC was similar to IFN-γ expression after 96 h. IL-12 p40 mRNA was clearly expressed in PPD-stimulated cells treated with anti-CD80, CD86, or CD80/86 antibodies after a 6-h stimulation. However, IL-12 p40 mRNA was not detected after neutralization of CD40L molecules in PPD-stimulated cells. In HTR-PBMC, IFN-γ mRNA expression was more increased compared with that of Tbp-PMC, whereas IL-12 p40 mRNA

expression was similar or slightly lower to that of Tbp-PMC (Fig. 4C).

**ELISA:** As shown in Fig. 5(A), PPD-induced IL-12 p40 levels were equivalent to levels in cultures containing neutralizing anti-CD80, CD86, or CD80/86 antibodies ( $p > 0.01$ ). PPD-induced IL-12 p40 levels in the presence of anti-CD80 were relatively higher than those observed after PPD stimulation. However, co-culture with a neutralizing antibody to CD40L led to a significant decrease in IL-12 p40 production in Tbp-PMC (1.7-fold,  $p < 0.05$ ; Fig. 5A). In addition, IFN- $\gamma$  production in Tbp-PMC was significantly reduced by co-culture with the neutralizing antibody to CD40L (2-fold,  $p < 0.05$ ; Fig. 5B). IFN- $\gamma$  levels stimulated with PPD after co-culture with neutralizing antibodies to CD80, CD86, or both were similar to levels detected after PPD only. In HTR-PBMC, IL-12 p40 and IFN- $\gamma$  levels were approximately equivalent to those of Tbp-PMC.

## Discussion

An effective immune response against *M. tuberculosis* requires the coordinated interaction of APC and lymphocytes, and therefore secondary signals, such as the interaction of co-stimulatory molecules, are very important for T cell activation. In this study, we determined the effect of CD80, CD86 and CD40L co-stimulatory molecule neutralization on IFN- $\gamma$  and IL-12 responses to PPD Ag in Tbp-PMC. PPD-stimulated Tbp-PMC was found to express significantly more ( $p < 0.001$ ) IL-12 than Ag-stimulated MG-PMC, and IL-12 production in individual patients correlated with PPD Ag-induced IFN- $\gamma$  secretion after stimulation for 96 h. In addition, blocking CD40/CD40L interactions decreased IL-12 and IFN- $\gamma$  production in Tbp-PMC.

IL-12 plays a crucial role in IFN- $\gamma$  induction by T lymphocytes (11,23,24), and IL-12-deficient mice are highly susceptible to infection by *M. tuberculosis* (25). Interactions between CD40 on antigen-presenting cells and CD40L on T cells enhance the Th1 response by inducing macrophages and dendritic cells (17,26,27) to produce interleukin-12 (IL-12), and by enhancing the expression of co-stimulatory molecules of the B7 family on antigen-presenting cells (28-30).

Interaction between the CD40 receptor on APC and its ligand (CD40L) on activated T cells plays a critical role in immunity to intracellular pathogens by up-regulating the production of IL-12 (31,32). CD40- or CD40L-deficient mice have an increased susceptibility to leishmanial infection, and show an impaired priming of Th1-type cells, correlating with a lack of activation of the macrophage effector functions required for parasite clearance (21,33). By contrast, CD40L-deficient mice show no difference in sus-

ceptibility to *M. tuberculosis* infection compared to wild-type mice (19), suggesting that cell-mediated immunity and protection against mycobacteria develop independently of CD40L.

The current study suggests that mycobacterial Ag-stimulated IL-12 and IFN- $\gamma$  production by Tbp-PMC and HTR-PBMC involves CD40/CD40L interactions. Our evidence also partially agrees with others who showed that CD40L expression correlated directly with *M. tuberculosis*-stimulated IFN- $\gamma$  production by PBMC from tuberculosis patients and HTR (34). This group also showed that a CD40L agonist increased *M. tuberculosis*-induced IFN- $\gamma$  production by PBMC, and anti-CD40 or anti-CD40L antibodies reduced IFN- $\gamma$  production. It is therefore possible that additional stimulation of the CD40/CD40L signaling pathway in mycobacterium-infected antigen presenting cells (APC) may further enhance IL-12 production, and consequently Th1 protective immunity.

Infection of dendritic cells with live *M. tuberculosis* bacilli results in increased APC surface expression of the co-stimulatory molecules CD54, CD40, and CD80, as well as MHC class I molecules (35). Additionally, another study showed that infection of a conditionally immortalized dendritic cell line with *M. tuberculosis* resulted in up-regulation of CD80 and CD86 co-stimulatory molecules, and the induction of several inflammatory cytokines, including tumor necrosis factor- $\alpha$  and IL-6, IL-1 $\beta$ , and IL-12 (36). However, in the present study, neutralization of CD80, CD86, or both did not affect IL-12 and IFN- $\gamma$  production. One possible explanation for these differences might be that the antigen-expressing cells in Tbp-PMC used in our study might function differently from dendritic cells. We are now in the process of determining which cells are the principal APC in Tbp-PMC.

In terms of IFN- $\gamma$  production, our data correlate well with other reports (11). Tuberculous pleural fluid lymphocytes underwent greater blastic transformation and produced more IFN- $\gamma$  than pleural lymphocytes of tuberculin-positive non-tuberculous patients, whereas the opposite occurred in peripheral lymphocytes. In tuberculin-negative non-tuberculous patients, there were no lymphoblastic responses in either the pleural fluid or peripheral blood. Our data, taken together with these previous findings, suggest clonal expansion of mycobacterial Ag-responding T lymphocytes in the pleural compartment of Tbp patients. A recent report also indicated that IFN- $\gamma$  may provide an afferent feedback signal that enhances IL-12 p70 expression through selective up-regulation of IL-12 p35 mRNA levels (37). Based on these results and our own data, we hypothesize that positive feedback via IL-12-IFN- $\gamma$

contributes to the characteristic cell-mediated immune response and facilitates the development of Th1 cells.

The results reported here suggest that CD40/CD40L interactions contribute to local protective immunity in Tbp patients via increased IL-12 and IFN- $\gamma$  production. Future studies will clarify the molecular mechanisms of Th1 protective immunity via CD40/CD40L interactions.

## References

- Pettersson T, Klockars M, Hellstrom P-E, Riska H, Wangel A: T- and B-lymphocytes in pleural effusions. *Chest* 73; 49-51, 1978
- Barnes PF, Mistry SD, Cooper CL, Pirmez C, Rea TH, Modlin RL: Compartmentalization of a CD4<sup>+</sup> T-lymphocyte subpopulation in tuberculous pleuritis. *Immunol* 142;1114-1119, 1989
- Shimokata K, Kawachi H, Kishimoto H, Maeda F, Yasuhiko I: Local cellular immunity in tuberculous pleurisy. *Am Rev Respir Dis* 126;822-824, 1982
- Ribera E, Ocana I, Martinez-Vazquez JM, Rossell M, Espanol T, Ruibal A: High level of interferon gamma in tuberculous pleural effusion. *Chest* 93;308-311, 1988
- Shimokata K, Saka H, Murate T, Hasegawa Y, Hasegawa T: Cytokine content in pleural effusion. Comparison between tuberculous and carcinomatous pleurisy. *Chest* 99;1103-1107, 1991
- Valdes L, San Jose E, Alvarez D, Sarandeses A, Pose A, Chomon B, Alvarez-Dobano JM, Salgueiro M, Rodriguez Suarez JR: Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma. *Chest* 103;458-465, 1993
- Aoki Y, Katoh O, Nakanishi Y, Kuroki S, Yamada H: A comparison study of IFN-gamma, ADA, and CA125 as the diagnostic parameters in tuberculous pleuritis. *Respir Med* 88;139-143, 1994
- Scott P, Kaufmann SH: The role of T-cell subsets and cytokines in the regulation of infection. *Immunol Today* 12;346-348, 1991
- Sher A, Coffman RL: Regulation of immunity to parasites by T cells and T cell-derived cytokines. *Annu Rev Immunol* 10;385-409, 1992
- Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL: Cytokine production at the site of disease in human tuberculosis. *Infect Immun* 61;3482-3489, 1993
- Zhang M, Gately MK, Wang E, Gong J, Wolf SF, Lu S, Modlin RL, Barnes PF: Interleukin 12 at the site of disease in tuberculosis. *J Clin Invest* 93;1733-1739, 1994
- Ribera E, Espanol T, Martinez-Vazquez JM, Ocana I, Encabo G: Lymphocyte proliferation and gamma-interferon production after "in vitro" stimulation with PPD. Differences between tuberculous and nontuberculous pleurisy in patients with positive tuberculin skin test. *Chest* 97;1381-1385, 1990
- Ferrer J: Pleural tuberculosis. *Eur Respir J* 10;942-947, 1997
- Song CH, Jo EK, Kim SH, Kim HJ, Suhr JW, Paik TH, Nam HH, Lim JH, Kim UO, Lee JS, Park JK: Increased IL-12, but depressed IL-18 production after in vitro stimulation with a 30-kDa mycobacterial antigen in tuberculous pleural mononuclear cells. *J Bac Virol* 31;1-10, 2001
- Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, Schuler G: Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. *Eur J Immunol* 26;659-668, 1996
- Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM, Kelleher K, Herrmann SH, Clark SC, Azzoni L, Chan SH, Trinchieri G, Perussia B: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. *J Immunol* 146;3074-3081, 1991
- McDyer JF, Goletz TJ, Thomas E, June CH, Seder RA: CD40 ligand/CD40 stimulation regulates the production of IFN-gamma from human peripheral blood mononuclear cells in an IL-12- and/or CD28-dependent manner. *J Immunol* 160;1701-1707, 1998
- Chougnat C, Thomas E, Landay AL, Kessler HA, Buchbinder S, Scheer S, Shearer GM: CD40 ligand and IFN-gamma synergistically restore IL-12 production in HIV-infected patients. *Eur J Immunol* 28;646-656, 1998
- Campos-Neto A, Ovendale P, Bement T, Koppi TA, Fanslow WC, Rossi MA, Alderson MR: CD40 ligand is not essential for the development of cell-mediated immunity and resistance to *Mycobacterium tuberculosis*. *J Immunol* 160;2037-2041, 1998
- Callard RE, Armitage RJ, Fanslow WC, Spriggs MK: CD40 ligand and its role in X-linked hyper-IgM syndrome. *Immunol Today* 14;559-564, 1993
- Kamanaka M, Yu P, Yasui T, Yoshida K, Kawabe T, Horii T, Kishimoto T, Kikutani H: Protective role of CD40 in *Leishmania major* infection at two distinct phases of cell-mediated immunity. *Immunity* 4;275-281, 1996
- Song CH, Kim HJ, Park JK, Lim JH, Kim UO, Kim JS, Paik TH, Kim KJ, Suhr JW, Jo EK: Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30- or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis. *Infect Immun* 68;4477-4484, 2000
- Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. *Blood* 84;4008-4027, 1994
- Kim J, Uyemura K, Van Dyke MK, Legaspi AJ, Rea TH, Shuai K, Modlin RL: A role for IL-12 receptor expression and signal transduction in host defense in leprosy. *J Immunol* 167;779-786, 2001
- Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M, Torigoe K, Tanimoto T, Fukuda S, Ikeda M, Okamura H, Kurimoto M: Cloning of the cDNA for human IFN-gamma-inducing factor, expression in *Escherichia coli*, and studies on the biologic activities of the protein. *J Immunol* 156;4274-4279, 1996
- Kato T, Hakamada R, Yamene H, Nariuchi H: Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. *J Immunol* 156;3932-3938, 1996
- Stber E, Strober W, Neurath M: Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming

- of T helper 1 cells through the inhibition of interleukin 12 secretion. *J Exp Med* 183;693-698, 1996
28. Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK: Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. *Cancer Res* 58;2965-2968, 1998
  29. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. *J Exp Med* 177;925-935, 1993
  30. Yang Y, Wilson JM: CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. *Science* 273;1862-1864, 1996
  31. Ferlin WG, Vonderweid T, Cottrez F, Ferrick DA, Coffman RL, Howard MC: The induction of a protective response in *Leishmania major*-infected BALB/c mice with anti-CD40 monoclonal antibody. *Eur J Immunol* 28;525-531, 1998
  32. Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, Restifo NP, Seder RA: CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. *J Immunol* 161;4563-4571, 1998
  33. Soong L, Xu JC, Grewal IS, Kima P, Sun JR, Longley BJ, Ruddle NH, McMahonpratt D, Flavell RA: Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to *Leishmania amazonensis* infection. *Immunity* 4;263-273, 1996
  34. Samten B, Thomas EK, Gong J, Barnes PF: Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis. *Infect Immun* 68;3002-3006, 2000
  35. Henderson RA, Watkins SC, Flynn JL: Activation of human dendritic cells following infection with *Mycobacterium tuberculosis*. *J Immunol* 159;635-643, 1997
  36. Tascon RE, Soares CS, Ragno S, Stavropoulos E, Hirst EM, Colston MJ: *Mycobacterium tuberculosis*-activated dendritic cells induce protective immunity in mice. *Immunology* 99;473-480, 2000
  37. Fulton SA, Cross JV, Toossi ZT, Boom WH: Regulation of interleukin-12 by interleukin-10, transforming growth factor- $\beta$ , tumor necrosis factor- $\alpha$ , and interferon- $\gamma$  in human monocytes infected with *Mycobacterium tuberculosis* H37Ra. *J Inf Dis* 178;1105-1114, 1998
-